FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.
EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.
15 cl, 20 tbl, 21 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
FAST ACHIEVEMENT AND/OR TERMINATION OF SIGNIFICANT STABLE DRUG DELIVERY | 2014 |
|
RU2703471C2 |
RAPID ACCOMPLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STABLE DRUG DELIVERY | 2010 |
|
RU2753280C2 |
METHOD OF TREATING INSULIN-INDEPENDENT DIABETES AND OBESITY, OSMOTIC DELIVERY SYSTEM AND METHOD FOR MAKING IT | 2008 |
|
RU2440097C2 |
POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2572703C2 |
METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
METHOD OF PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES AND COMPOSITIONS CONTAINING THEREOF | 2015 |
|
RU2702690C2 |
OCTREOTIDE DELIVERY FROM DRY DOSAGE FORMS | 2009 |
|
RU2518745C2 |
LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
Authors
Dates
2015-04-10—Published
2010-09-21—Filed